Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Sodium Fluoride F 18
Generic Name
Sodium Fluoride F 18
Active Ingredient
Sodium Fluoride F-18Category
Other
Variants
3
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Sodium Fluoride F 18, you must consult a qualified healthcare professional.
Detailed information about Sodium Fluoride F 18
Sodium Fluoride F-18 is a radioactive diagnostic agent used in Positron Emission Tomography (PET) to visualize areas of altered osteogenic activity in the skeletal system.
The standard adult dose for Sodium Fluoride F-18 PET imaging typically ranges from 300 to 600 Megabecquerels (MBq), which is equivalent to 8 to 16 Millicuries (mCi). The exact dose is calculated by the nuclear medicine physician based on the patient's body weight, the specific PET scanner being used, and the clinical indication for the scan. For most adults, a dose of 370 MBq (10 mCi) is standard. The injection is administered as a slow intravenous bolus.
Sodium Fluoride F-18 is used in pediatric patients, but the dosage must be strictly adjusted based on body weight to minimize radiation exposure. The recommended pediatric dose is typically 2.1 MBq per kilogram (0.057 mCi/kg) of body weight. Healthcare providers follow the 'As Low As Reasonably Achievable' (ALARA) principle to ensure children receive the minimum amount of radiation necessary to obtain a high-quality diagnostic image. The minimum dose is usually around 19 MBq (0.5 mCi).
Patients with impaired kidney function (renal insufficiency) may require special consideration. Since the drug is cleared through the urine, poor kidney function can lead to slower clearance of the radioactivity from the body, potentially increasing the radiation dose to the bladder and kidneys. While the injected dose might not always be reduced, the patient may be instructed to increase fluid intake significantly to help flush the agent out.
No dosage adjustments are typically required for patients with liver disease, as Sodium Fluoride F-18 is not metabolized by the liver and does not rely on hepatic pathways for excretion.
In elderly patients, the primary concern is often underlying renal function. Healthcare providers will assess the glomerular filtration rate (GFR) to ensure the patient can adequately eliminate the radiopharmaceutical after the scan is complete.
Sodium Fluoride F-18 is administered exclusively by a healthcare professional via intravenous injection.
Since Sodium Fluoride F-18 is administered for a scheduled imaging procedure by a professional, a 'missed dose' in the traditional sense does not occur. If you miss your appointment, the dose prepared for you will likely expire due to its short 110-minute half-life, and a new dose will need to be ordered for a rescheduled time.
An overdose of Sodium Fluoride F-18 is extremely rare because the dose is precisely calculated and measured before administration. In the event of an accidental administration of an excessive dose, the primary risk is increased radiation exposure. The management strategy involves 'forced diuresis'—encouraging the patient to drink large amounts of fluids and urinate frequently to speed up the removal of the radioactive material from the body.
> Important: Follow your healthcare provider's dosing and preparation instructions exactly. Do not attempt to adjust your appointment time without notifying the nuclear medicine department, as the medication is time-sensitive.
Sodium Fluoride F-18 is generally very well tolerated, and most patients do not experience any noticeable side effects from the drug itself. Because it is a diagnostic tracer used in very small (microgram) quantities, it does not have the same side effect profile as therapeutic medications. However, some patients may experience:
Sodium Fluoride F-18 is a radioactive material and must be handled with extreme care by authorized personnel only. The primary safety concern for the patient is the radiation dose to the internal organs, particularly the bladder. To minimize this risk, patients must be well-hydrated before the procedure and must urinate as often as possible for several hours after the injection. This helps to 'flush' the radioactive fluoride out of the urinary system, reducing the time the bladder wall is exposed to radiation.
No FDA black box warnings for Sodium Fluoride F-18.
There are no medications that are strictly contraindicated (forbidden) for use with Sodium Fluoride F-18. Because it is a diagnostic tracer used in minute quantities, it does not interfere with the chemical action of other drugs. However, certain drugs may interfere with the accuracy of the test results.
Sodium Fluoride F-18 is classified as FDA Pregnancy Category C (under the older system). There are no adequate and well-controlled studies in pregnant women. However, it is known that radioactive substances can cross the placenta and be absorbed by the fetus. The fetal skeleton is rapidly developing, meaning it would take up a significant amount of the radioactive fluoride. This poses a risk of radiation-induced injury or future malignancy. If a scan is absolutely necessary, the lowest possible dose should be used, and the patient should be informed of the risks.
It is not known exactly how much Sodium Fluoride F-18 is excreted in human breast milk, but many radiopharmaceuticals are present in milk. To minimize risk to the nursing infant, a lactating woman should pump and discard breast milk for at least 12 to 24 hours after receiving the injection. During this time, the infant should be fed with previously expressed milk or formula.
Sodium Fluoride F-18 is used in children to evaluate bone lesions. However, interpretation must be done by a specialist, as children have 'active growth plates' (epiphyseal plates) that naturally take up large amounts of fluoride. This is normal for a growing child but can look like an abnormality to an untrained eye. Dosing must be strictly weight-based to limit radiation exposure.
Sodium Fluoride F-18 acts as a bone-seeking radiopharmaceutical. The mechanism is based on simple ion exchange. The skeletal hydroxyapatite crystal $[Ca_{10}(PO_4)_6(OH)_2]$ has hydroxyl groups ($OH^-$) that can be replaced. The Fluoride F-18 ion ($^{18}F^-$) has a similar size and charge to the hydroxyl ion. When the tracer reaches the bone surface, the $^{18}F^-$ replaces the $OH^-$ to form $^{18}F$-labeled fluorapatite. This process occurs preferentially in areas with high blood flow and high bone turnover (osteoblastic activity).
Sodium Fluoride F-18 does not produce a measurable physiological effect at the doses used for imaging. It does not stimulate or inhibit any receptors or enzymes. The 'effect' is purely the emission of radiation for detection. The time to onset for bone visualization is roughly 30-60 minutes, and the 'duration of effect' is limited by the physical decay of the isotope (half-life of 110 minutes).
| Parameter | Value |
|---|---|
Common questions about Sodium Fluoride F 18
Sodium Fluoride F-18 is primarily used as a diagnostic tool in PET scans to identify areas of abnormal bone activity. It is most commonly employed to detect bone metastases, which is when cancer spreads from another part of the body, like the prostate or breast, to the skeleton. Because it is highly sensitive, it can find bone changes much earlier than a traditional X-ray. It may also be used to evaluate primary bone tumors or investigate unexplained bone pain. Your doctor will use the resulting images to help stage cancer or monitor how well a treatment is working.
The most common side effects are very mild and related to the injection process rather than the drug itself. Patients may experience slight pain, redness, or a small bruise at the injection site. A very small percentage of people report a temporary metallic taste in their mouth or a mild headache after the procedure. Because the amount of the chemical injected is so tiny, typical 'drug' side effects like upset stomach or drowsiness are extremely rare. Most people feel completely normal during and after the administration.
There is no direct chemical interaction between alcohol and Sodium Fluoride F-18, but it is generally recommended to avoid alcohol before and after your scan. Alcohol can lead to dehydration, and being well-hydrated is essential for flushing the radioactive tracer out of your system through your urine. Proper hydration protects your bladder from unnecessary radiation exposure. If you do consume alcohol, ensure you balance it with plenty of water. Always follow the specific preparation instructions provided by your imaging center.
Sodium Fluoride F-18 is generally not recommended during pregnancy because it involves exposure to ionizing radiation. The radioactive fluoride can cross the placenta and be taken up by the developing fetus's bones, which could potentially cause harm or increase the risk of cancer later in the child's life. Doctors will only perform this scan on a pregnant woman if the diagnostic information is critical for a life-threatening situation. If you are pregnant or think you might be, you must inform your healthcare provider before the injection. Alternative imaging methods that do not use radiation, like MRI, may be considered instead.
Sodium Fluoride F-18 begins moving toward your bones immediately after it is injected into your vein. It typically takes about 30 to 60 minutes for enough of the tracer to accumulate in the skeletal system to produce high-quality images. During this waiting period, you will usually be asked to rest quietly in a waiting room. The actual PET scan itself, which happens after this waiting period, usually takes another 20 to 45 minutes. The entire process from injection to the end of the scan generally lasts about two hours.
Sodium Fluoride F-18 is not a daily medication that you 'take' over time; it is a one-time injection given for a specific medical test. Therefore, there is no concern about 'stopping' the medication or experiencing withdrawal symptoms. Once the injection is given, the radioactivity naturally disappears from your body through decay and urination within about 24 hours. You do not need to follow any tapering schedule. If you decide you do not want the scan, you simply inform your doctor before the injection is administered.
Because Sodium Fluoride F-18 is administered by a professional during a scheduled hospital or clinic visit, you cannot 'miss a dose' in the way you might miss a pill at home. If you miss your appointment, the medication prepared for you will lose its radioactivity and become useless within a few hours. You will need to contact your imaging center to reschedule the procedure so they can order a fresh dose. There are no health consequences to missing the appointment, other than the delay in getting your diagnostic results.
No, Sodium Fluoride F-18 does not cause weight gain. It is a diagnostic tracer used in a single, minute dose that has no effect on your metabolism, appetite, or fat storage. It does not contain calories or hormones that influence body weight. Any changes in weight you may be experiencing are likely related to your underlying medical condition or other treatments you may be receiving, such as chemotherapy or steroids. If you are concerned about weight changes, you should discuss them with your primary care physician or oncologist.
In most cases, you can continue taking your regular medications before a Sodium Fluoride F-18 scan. However, certain drugs that affect bone health, such as bisphosphonates (like Fosamax) or denosumab (like Prolia), can sometimes interfere with how clearly the scan shows bone abnormalities. It is very important to provide your doctor with a full list of all prescriptions, over-the-counter drugs, and supplements you are taking. They will tell you if any specific medications need to be timed differently around your scan. Most routine medications for blood pressure, diabetes, or pain will not affect the scan.
Sodium Fluoride F-18 is a radiopharmaceutical that is produced by various specialized nuclear pharmacies and cyclotrons. While it may not be referred to by a 'brand name' in the same way as drugs like Lipitor or Tylenol, it is essentially a standardized chemical compound. Different manufacturers may produce it, but the active ingredient—the F-18 fluoride ion—is the same across all providers. Because it is a diagnostic agent used in a clinical setting, patients usually do not have to choose between a brand and a generic; the facility will provide the version they have in stock.
While extremely rare, serious reactions can occur. You should inform the medical staff immediately if you experience any of the following during or after the injection:
> Warning: Stop the procedure and call for help if you experience:
There are no known long-term 'pharmacological' side effects of Sodium Fluoride F-18, as the drug is completely gone from the body within 24 hours. The primary long-term consideration is cumulative radiation exposure. Every radiopharmaceutical contributes to a person's lifetime radiation dose. While a single NaF F-18 scan is within the safety limits for diagnostic procedures, repeated scans over many years can theoretically increase the risk of cancer. However, the diagnostic benefit of identifying bone metastases usually far outweighs this theoretical risk.
There are currently no FDA black box warnings for Sodium Fluoride F-18. It is considered a safe and effective diagnostic tool when used according to established protocols.
Report any unusual symptoms, even if they seem minor, to your healthcare provider or the nuclear medicine technologist during your scan. They are trained to manage any immediate reactions to the radiopharmaceutical.
There are no specific long-term lab tests required for patients receiving a single dose of Sodium Fluoride F-18. However, during the procedure, the technologist will monitor the injection site for signs of 'extravasation' (where the drug leaks out of the vein into the surrounding tissue). If you have pre-existing kidney disease, your doctor may monitor your serum creatinine levels before the scan.
Sodium Fluoride F-18 does not cause drowsiness or impairment of cognitive function. You should be able to drive yourself home after the scan unless you have received a sedative for claustrophobia during the PET scan itself. Always check with your doctor if you feel lightheaded after the procedure.
There are no known direct interactions between alcohol and Sodium Fluoride F-18. However, alcohol can cause dehydration. Because hydration is critical for clearing the radiation from your body, it is recommended to avoid alcohol for 24 hours before and after the scan.
As this is a one-time diagnostic injection, there are no tapering requirements or withdrawal syndromes associated with Sodium Fluoride F-18.
> Important: Discuss all your medical conditions, especially pregnancy or kidney issues, with your healthcare provider before starting Sodium Fluoride F-18.
There are no known food interactions with Sodium Fluoride F-18. Unlike some other PET tracers (like FDG which requires fasting to manage glucose levels), Sodium Fluoride F-18 uptake is not affected by blood sugar or recent meals. However, staying hydrated with water is essential.
Sodium Fluoride F-18 does not interfere with standard blood chemistry or hematology tests. However, the presence of radioactivity in the blood and urine for the first 12-24 hours after the scan could potentially interfere with certain highly sensitive radioimmunoassays (specialized lab tests that also use radioactive markers). If you need blood work done, it is best to wait 24 hours after your PET scan.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those that affect your bones.
There is no known cross-sensitivity between Sodium Fluoride F-18 and iodinated contrast media (used in CT scans) or gadolinium-based contrast (used in MRI). If you are allergic to CT or MRI dye, you can usually still safely receive a Sodium Fluoride F-18 injection.
> Important: Your healthcare provider will evaluate your complete medical history, including kidney function and pregnancy status, before prescribing Sodium Fluoride F-18.
In clinical studies, no overall differences in safety or effectiveness were observed between elderly patients (65 and over) and younger patients. The main concern in this population is the higher prevalence of decreased renal function. Because the drug is cleared renally, elderly patients should be monitored for adequate hydration to ensure the tracer is eliminated promptly.
Patients with a reduced Glomerular Filtration Rate (GFR) will experience slower clearance of the tracer from the blood. This can lead to 'blurry' images because the background radioactivity remains high. Furthermore, it increases the radiation dose to the kidneys and bladder. In patients with GFR < 30 mL/min, the diagnostic utility of the scan may be limited.
Since the liver is not involved in the uptake or excretion of Sodium Fluoride F-18, no specific precautions or dose adjustments are required for patients with liver cirrhosis or hepatic failure.
> Important: Special populations require individualized medical assessment to balance the diagnostic benefits against the risks of radiation exposure.
| Protein Binding | Negligible |
| Physical Half-life | 109.7 minutes |
| Tmax (Bone Uptake) | 45 - 60 minutes |
| Metabolism | None (Physical decay to Oxygen-18) |
| Excretion | Renal (20% - 50% in first 3 hours) |
The molecular formula is $Na^{18}F$. It has a molecular weight of approximately 41.0 (depending on the isotope). It is highly soluble in water. The Fluorine-18 isotope is produced in a cyclotron by proton irradiation of Oxygen-18 enriched water. It decays by positron ($eta^+$) emission to stable Oxygen-18, with a maximum positron energy of 0.633 MeV.
Sodium Fluoride F-18 is classified as a Radioactive Diagnostic Agent and a Radiopharmaceutical. It is part of a group of agents used in Positron Emission Tomography (PET). Other drugs in this broad category include Fludeoxyglucose F-18 (FDG) and Gallium Ga-68 Dotatate, though these target different biological processes (glucose metabolism and somatostatin receptors, respectively).